AI Article Synopsis
- Intrahepatic artery infusion of 4' epidoxorubicin was studied as a treatment for liver tumors, chosen for its effective therapeutic levels in the liver.
- Seven patients with primary liver cancer and twenty with metastatic colon cancer were treated weekly, with only minor toxicity reported; one patient had temporary cardiac issues.
- While there were no responses for primary liver cancer, 30% of metastatic colorectal patients showed a positive response, suggesting not enough efficacy to recommend epidoxorubicin as a first-line treatment for colorectal cancer.
Article Abstract
Primary and metastatic gastrointestinal tumours in the liver have been treated by intrahepatic artery infusion of chemotherapeutic drugs in an attempt to increase the efficacy of the administered agents. Among the several active agents, 4' epidoxorubicin, an anthracycline analogue, was selected for this study because of the therapeutic level reached in the liver by this drug. Seven patients with primary hepatic carcinoma and twenty with metastatic adenocarcinoma of the colon to the liver received intraarterial hepatic infusion of epidoxorubicin at the dosage of 30 mg weekly. No haematological or gastrointestinal grade 3-4 toxicity was recorded, only one patient experienced transient cardiac toxicity. No objective response was observed in primary hepatic carcinoma and six objective responses, 1 complete and 5 partial (30%), were achieved in metastatic colorectal cancer patients. This results is not far from those reported with FUDR, but does not justify epidoxorubicin in colorectal cancer patients as first line intraarterial treatment.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!